ATE325796T1 - Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente - Google Patents
Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamenteInfo
- Publication number
- ATE325796T1 ATE325796T1 AT02760555T AT02760555T ATE325796T1 AT E325796 T1 ATE325796 T1 AT E325796T1 AT 02760555 T AT02760555 T AT 02760555T AT 02760555 T AT02760555 T AT 02760555T AT E325796 T1 ATE325796 T1 AT E325796T1
- Authority
- AT
- Austria
- Prior art keywords
- linear
- branched
- alkyl
- aryl
- alkenyl
- Prior art date
Links
- 102000007471 Adenosine A2A receptor Human genes 0.000 title abstract 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- UCJKLYSNBVUUDM-UHFFFAOYSA-N 2-(2h-triazol-4-yl)-7h-purine Chemical compound N=1C=C2NC=NC2=NC=1C1=CNN=N1 UCJKLYSNBVUUDM-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Chemical group 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000465A ITRM20010465A1 (it) | 2001-07-31 | 2001-07-31 | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE325796T1 true ATE325796T1 (de) | 2006-06-15 |
Family
ID=11455703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02760555T ATE325796T1 (de) | 2001-07-31 | 2002-07-25 | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7230102B2 (https=) |
| EP (1) | EP1412354B1 (https=) |
| JP (1) | JP4366186B2 (https=) |
| KR (1) | KR100884818B1 (https=) |
| CN (1) | CN1271070C (https=) |
| AT (1) | ATE325796T1 (https=) |
| AU (1) | AU2002326146B2 (https=) |
| BR (1) | BR0211550A (https=) |
| CA (1) | CA2451279C (https=) |
| DE (1) | DE60211343T2 (https=) |
| DK (1) | DK1412354T3 (https=) |
| ES (1) | ES2263810T3 (https=) |
| HU (1) | HU228985B1 (https=) |
| IT (1) | ITRM20010465A1 (https=) |
| MX (1) | MXPA04000886A (https=) |
| PL (1) | PL217269B1 (https=) |
| PT (1) | PT1412354E (https=) |
| WO (1) | WO2003011864A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60206756T2 (de) * | 2001-06-29 | 2006-07-13 | CV Therapeutics, Inc., Palo Alto | Purin derivate als a2b adenosin rezeptor antagonisten |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| ATE355291T1 (de) * | 2001-12-18 | 2006-03-15 | Cv Therapeutics Inc | A2a adenosinrezeptorantagonisten |
| WO2005092893A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | ９置換−８−オキソアデニン化合物 |
| CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK |
| TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| EP2132209B8 (en) | 2007-03-19 | 2014-04-16 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
| EP2139894B1 (en) | 2007-03-19 | 2011-10-26 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| JP5401329B2 (ja) * | 2007-03-20 | 2014-01-29 | キュリス，インコーポレイテッド | Ｈｓｐ９０インヒビターとしての縮合アミノピリジン |
| WO2008114819A1 (ja) | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| KR20100016289A (ko) * | 2007-05-08 | 2010-02-12 | 아스트라제네카 아베 | 면역-조정 특성의 이미다조퀴놀린 |
| UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
| WO2009091032A1 (ja) | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
| US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| AU2009266889B2 (en) | 2008-07-03 | 2013-05-02 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
| NZ590793A (en) * | 2008-07-23 | 2012-07-27 | Kyowa Hakko Kirin Co Ltd | Therapeutic agent for migraine |
| HRP20150766T1 (hr) * | 2009-03-20 | 2015-08-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Oksidirani derivati triazolilpurina, korisni kao ligandi adenozinskog receptora a2a, te namijenjeni upotrebi kao medikamenti |
| US20120295863A1 (en) * | 2009-11-13 | 2012-11-22 | Yun-Lian Lin | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases |
| JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン |
| JP5714602B2 (ja) * | 2010-11-24 | 2015-05-07 | ヤマサ醤油株式会社 | 新規な２−アルキニル−ｎ９−プロパギルアデニンおよびその医薬用途 |
| JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ［４，５−ｃ］キノリン−１−イル誘導体 |
| ES2627433T3 (es) | 2010-12-17 | 2017-07-28 | Sumitomo Dainippon Pharma Co., Ltd. | Derivados de purina |
| CA2902833A1 (en) | 2013-03-15 | 2014-09-18 | Syngenta Participations Ag | Microbicidally active imidazopyridine derivatives |
| CN105622495A (zh) * | 2016-03-23 | 2016-06-01 | 叶芳 | 4-氯-3-硝基吡啶及其制备方法 |
| ES2957548T3 (es) * | 2016-04-15 | 2024-01-22 | Univ Oxford Innovation Ltd | Moduladores del receptor de adenosina para el tratamiento de los trastornos del ritmo circadiano |
| WO2025080645A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating bullous pemphigoid |
| GB202319534D0 (en) * | 2023-12-19 | 2024-01-31 | Circadian Therapeutics Ltd | Dosage regimen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU626983B2 (en) | 1989-01-31 | 1992-08-13 | Whitby Research, Inc. | N6-substituted 9-methyladenines |
| US5670501A (en) * | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| AU1688599A (en) * | 1998-01-05 | 1999-07-26 | Eisai Co. Ltd. | Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| DE60206756T2 (de) * | 2001-06-29 | 2006-07-13 | CV Therapeutics, Inc., Palo Alto | Purin derivate als a2b adenosin rezeptor antagonisten |
| ITRM20010465A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
-
2001
- 2001-07-31 IT IT2001RM000465A patent/ITRM20010465A1/it unknown
-
2002
- 2002-07-25 ES ES02760555T patent/ES2263810T3/es not_active Expired - Lifetime
- 2002-07-25 CN CNB028138481A patent/CN1271070C/zh not_active Expired - Fee Related
- 2002-07-25 AU AU2002326146A patent/AU2002326146B2/en not_active Ceased
- 2002-07-25 DE DE60211343T patent/DE60211343T2/de not_active Expired - Lifetime
- 2002-07-25 WO PCT/IT2002/000489 patent/WO2003011864A1/en not_active Ceased
- 2002-07-25 MX MXPA04000886A patent/MXPA04000886A/es active IP Right Grant
- 2002-07-25 PT PT02760555T patent/PT1412354E/pt unknown
- 2002-07-25 EP EP02760555A patent/EP1412354B1/en not_active Expired - Lifetime
- 2002-07-25 AT AT02760555T patent/ATE325796T1/de active
- 2002-07-25 US US10/484,491 patent/US7230102B2/en not_active Expired - Fee Related
- 2002-07-25 JP JP2003517056A patent/JP4366186B2/ja not_active Expired - Fee Related
- 2002-07-25 PL PL368409A patent/PL217269B1/pl unknown
- 2002-07-25 DK DK02760555T patent/DK1412354T3/da active
- 2002-07-25 BR BR0211550-6A patent/BR0211550A/pt not_active IP Right Cessation
- 2002-07-25 KR KR1020047000173A patent/KR100884818B1/ko not_active Expired - Fee Related
- 2002-07-25 HU HU0401987A patent/HU228985B1/hu not_active IP Right Cessation
- 2002-07-25 CA CA2451279A patent/CA2451279C/en not_active Expired - Fee Related
-
2007
- 2007-05-04 US US11/797,566 patent/US7528252B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT1412354E (pt) | 2006-09-29 |
| CN1271070C (zh) | 2006-08-23 |
| PL217269B1 (pl) | 2014-06-30 |
| JP4366186B2 (ja) | 2009-11-18 |
| JP2005500355A (ja) | 2005-01-06 |
| BR0211550A (pt) | 2004-07-13 |
| CA2451279C (en) | 2011-05-10 |
| ITRM20010465A1 (it) | 2003-01-31 |
| WO2003011864A1 (en) | 2003-02-13 |
| ITRM20010465A0 (it) | 2001-07-31 |
| DE60211343T2 (de) | 2007-05-10 |
| US20040204428A1 (en) | 2004-10-14 |
| US7230102B2 (en) | 2007-06-12 |
| AU2002326146B2 (en) | 2008-05-01 |
| CA2451279A1 (en) | 2003-02-13 |
| MXPA04000886A (es) | 2004-06-03 |
| HK1068334A1 (en) | 2005-04-29 |
| EP1412354A1 (en) | 2004-04-28 |
| ES2263810T3 (es) | 2006-12-16 |
| EP1412354B1 (en) | 2006-05-10 |
| PL368409A1 (en) | 2005-03-21 |
| KR100884818B1 (ko) | 2009-02-20 |
| US7528252B2 (en) | 2009-05-05 |
| US20070249638A1 (en) | 2007-10-25 |
| DE60211343D1 (de) | 2006-06-14 |
| CN1525974A (zh) | 2004-09-01 |
| DK1412354T3 (da) | 2006-09-18 |
| KR20040023641A (ko) | 2004-03-18 |
| HUP0401987A2 (hu) | 2005-01-28 |
| HUP0401987A3 (en) | 2012-12-28 |
| HU228985B1 (en) | 2013-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| BRPI0606319A2 (pt) | compostos farmacêuticos | |
| AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
| BRPI0409938A (pt) | derivados de azetidinacarboxamida e seu uso em terapia | |
| ATE453639T1 (de) | Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| DE60043349D1 (de) | Chinazolin-derivate und ihre verwendung als arzneimittel | |
| MY126862A (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
| HUP0401047A2 (hu) | Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények | |
| CY1105233T1 (el) | Παραγωγα κατιοντος 1,2,4 - θειαδιαζολιου ως ρυθμιστες υποδοχεα μελανοκορτινης | |
| MXPA05010621A (es) | Pirimidinonas sustituidas. | |
| MXPA04001240A (es) | Analogos antitumorales. | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| CY1107677T1 (el) | Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine | |
| CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| DE69924292D1 (de) | Pyrazol verbindungen und ihre verwendung | |
| CY1110145T1 (el) | Αλκυλο-υποκατεστημενες ινδολοκινοξαλινες | |
| BR0213026A (pt) | Compostos de imidazopiridina como reguladores do receptor 5-ht4 | |
| ATE505462T1 (de) | Neue biologischaktive molekü le | |
| ES2197003A1 (es) | Nuevos compuestos antagonistas de integrinas alfa. | |
| PT1022276E (pt) | Derivados de epoxissuccinamida | |
| ATE429421T1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| UA93668C2 (en) | N-(heteroaryl)-1h-indole-2-carboxamide derivatives and their use as vanilloid trpv1 receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1412354 Country of ref document: EP |